A promising solution to HLB is advancing to Phase 2 field trials following research by a Central State University scientist in Ohio. Anthony Arment, a molecular biologist and professor of biology at Central State University, played a key role in early research and ongoing consultation for the project.
Pop Test Oncology LLC, operating as Palisades Therapeutics, recently announced that its proprietary compound, TPR1, emerged as the leading candidate among more than 200 compounds evaluated by the U.S. Department of Agriculture (USDA). TPR1 will now be tested across citrus groves in replicated field trials designed to evaluate its effectiveness under commercial conditions.
Arment was asked by Palisades Therapeutics to build on previous studies involving Liberibacter crescens, the closest culturable relative of Candidatus Liberibacter asiaticus, the pathogen behind HLB.
“I performed the preliminary work testing the susceptibility of L. crescens to TPR1, as well as other potential compounds,” Arment said. “The initial research showed that L. crescens was extremely susceptible to antibiotics like TPR1, but we needed a molecule that could withstand light, heat and the environmental degradation conditions of Florida and stay viable within the trees long enough to be effective. Liberibacter spp. grow very slowly, so long-term exposure is critical to control, and TPR1 demonstrated all necessary traits as a potential solution.”
Although citrus is not grown in Ohio, and infected tissue cannot be transported, Arment continues to contribute by consulting on experimental planning and data interpretation.
TPR1 works by disrupting the pathogen’s ability to translate genes into proteins, a mechanism that makes it highly effective. The molecule was specifically engineered for agricultural resilience, maintaining stability in harsh environmental conditions.
Field trials will now assess TPR1’s impact on tree health, fruit quality, yield and its environmental profile. The goal is to halt HLB disease progression and restore productivity to infected trees.
In addition to the USDA and Central State University, Palisades collaborated with the Citrus Research and Development Foundation and Bayer Crop Science.
Michelle Heck of the USDA, Tom Minter of Palisades Therapeutics and Arment of Central State University lead the TPR1 project.
As TPR1 moves toward commercial deployment, Palisades Therapeutics is seeking a partner to assist with full Environmental Protection Agency/USDA registration and global market rollout.
Source: Central State University
Share this Post